MX1 and cancer: The results showed that more genes had alternative splicing events in the NU7441 treated cells with an increasing trend in AL (alternative last exon), MX (mutually exclusive exon), and IR (intron retention), the latter emerging as a promising cancer treatment target (Figure 3B) (24).